Market Place
Sourcing Support
VBI Vaccines Provides an Update on its Restructuring Proceedings
02 Aug 2024 //
BUSINESSWIRE
VBI Vaccines Initiates CCAA Restructuring Proceedings
30 Jul 2024 //
BUSINESSWIRE
VBI Vaccines Announces Health Canada Approval for PreHevbrio™
08 Dec 2022 //
BUSINESSWIRE
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901
22 Nov 2022 //
BUSINESSWIRE
VBI Vaccines to Participate in H.C. Wainwright 3rd Annual HBV Conference
17 Oct 2022 //
BUSINESSWIRE
VBI & Agenus Collaborates to Evaluate VBI-1901 in with Anti-PD-1 in PII Study
12 Oct 2022 //
BUSINESSWIRE
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent VBI-2901
29 Sep 2022 //
VBIVACCINES
VBI Vaccines Announces Presentation of Data of 3-Antigen Hepatitis B Vaccine
21 Sep 2022 //
BUSINESSWIRE
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
15 Sep 2022 //
BUSINESSWIRE
Valneva & VBI Vaccines Announce European Partnership for Marketing of PreHevbri®
07 Sep 2022 //
GLOBENEWSWIRE
VBI Vaccines Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
BUSINESS WIRE
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
12 Jul 2022 //
BUSINESSWIRE
VBI Vaccines Presents New Long-Term Data for 3-Antigen Adult Hepatitis B Vaccine
28 Jun 2022 //
BUSINESSWIRE
VBI Vaccines Receives U.S. FDA ODD for VBI-1901 in Glioblastoma
22 Jun 2022 //
BUSINESSWIRE
VBI Vaccines Announces Results of Annual General Meeting
22 Jun 2022 //
BUSINESSWIRE
VBI Vaccines to Participate in the Jefferies Healthcare Conference
07 Jun 2022 //
BUSINESSWIRE
VBI Vaccines Presents Updated PIIa Tumor Response and OS Data for VBI-1901
06 Jun 2022 //
BUSINESSWIRE
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbri
01 Jun 2022 //
BUSINESSWIRE
VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022
26 May 2022 //
BUSINESSWIRE
VBI Vaccines Presented HEOR for PreHevbrio at ISPOR
19 May 2022 //
BUSINESSWIRE
VBI Vaccines Reports First Quarter 2022 Financial Results
09 May 2022 //
BUSINESSWIRE
VBI Vaccines Announces EC Marketing Authorisation for PreHevbri
02 May 2022 //
BUSINESSWIRE
VBI Vaccines Announces Data from VBI-1901 in Recurrent Glioblastoma
28 Apr 2022 //
BUSINESSWIRE
VBI Vaccines Announces New Data and Progress of VBI-2900
05 Apr 2022 //
BUSINESSWIRE
VBI Vaccines Announces PreHevbrio is Now Available in the U.S. for Hepatitis B
29 Mar 2022 //
BUSINESSWIRE
VBI Vaccines to Participate in the 32nd Annual Oppenheimer Healthcare Conference
15 Mar 2022 //
BUSINESSWIRE
VBI Vaccines Reports Q4 and Full Year Financial Results for 2021
07 Mar 2022 //
BUSINESSWIRE
EMA expands nods for BMS, Eli Lilly, Novartis drugs
26 Feb 2022 //
FIERCEPHARMA
VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine
25 Feb 2022 //
BUSINESSWIRE
VBI Vaccines Announces PreHevbrio Recommended by CDC Advisory Committee
23 Feb 2022 //
BUSINESSWIRE
VBI Vaccines, Brii Bio Begin Dosing in 2nd Phase 2 Study in Chronic Hepatitis B
05 Jan 2022 //
BUSINESSWIRE
VBI Vaccines Files NDA for 3-Antigen Hepatitis B Vaccine to Health Canada
09 Dec 2021 //
BUSINESSWIRE
VBI Vaccines Announces FDA Approval of PreHevbrio for Hepatitis B in Adults
01 Dec 2021 //
BUSINESSWIRE
VBI Vaccines to Present New OS Data from Phase 2a Study of VBI-1901
01 Dec 2021 //
BUSINESSWIRE
VBI Vaccines Announces Q3 2021 Financial Results, Provides Corporate Update
08 Nov 2021 //
BUSINESSWIRE
VBI to present 3-Antigen Prophylactic HBV Vaccine Data at AASLD 2021
01 Nov 2021 //
BUSINESSWIRE
VBI Vaccines Announces Publication of Results from Pivotal Ph 3 Study, CONSTANT
13 Oct 2021 //
VBIVACCINES
VBI Vaccines to Publish Results from Phase 3 Study of VBI’s Hepatitis B Vaccine
13 Oct 2021 //
BUSINESSWIRE
VBI Vaccines: New Preclinical Data and Initiation of VBI-2905 Clinical Study
29 Sep 2021 //
BUSINESSWIRE
VBI Vaccines on the rise with increasingly bullish views on Wall Street
26 Aug 2021 //
SEEKINGALPHA
VBI Vaccines Announces Second Quarter 2021 Financial Results
02 Aug 2021 //
BUSINESS WIRE
VBI Vaccines Appoints Linda Bain to Board of Directors
07 Jul 2021 //
BUSINESSWIRE
VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hep B Jab
01 Jul 2021 //
BUSINESSWIRE
VBI Vaccines Announces Initial Positive Ph1 Data for Its eVLP Vaccine Candidate
29 Jun 2021 //
BUSINESSWIRE
VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine
29 Jun 2021 //
BUSINESSWIRE
Brii Bio and VBI Vaccines Present Positive Data from Phase 1b/2a on BRII-179
23 Jun 2021 //
BUSINESSWIRE
Brii Bio and VBI Vaccines present data from phase 1b / 2a study of BRII-179
22 Jun 2021 //
BUSINESSWIRE
VBI Vaccines to Present at Upcoming Scientific Conferences
17 Jun 2021 //
BUSINESSWIRE
VBI Vaccines to Present at Upcoming Scientific Conferences
16 Jun 2021 //
BUSINESSWIRE
VBI Vaccines Announces Abstracts Accepted for Poster Presentations at EASL 2021
09 Jun 2021 //
PRESS RELEASE
VBI Vaccines Announces Results of Annual General Meeting
09 Jun 2021 //
BUSINESSWIRE
VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for Recurrent GBM
08 Jun 2021 //
BUSINESSWIRE
VBI Vaccines to Present Updated Phase 2a Data for VBI-1901 at 2021 ASCO
20 May 2021 //
PRESS RELEASE
VBI Vaccines Announces Publication of Results from Pivotal Ph3 Study, PROTECT
12 May 2021 //
BUSINESSWIRE
VBI Announces Publication of Results from Pivotal Ph3 Study PROTECT
12 May 2021 //
PRESS RELEASE
VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021
04 May 2021 //
PRESS RELEASE
VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021
03 May 2021 //
BUSINESSWIRE
VBI Vaccines Announces Publication of Preclinical and Challenge Study Data
28 Apr 2021 //
BUSINESSWIRE
VBI Vaccines Announces Publication of Preclinical and Challenge Study Data
28 Apr 2021 //
VBIVACCINES
VBI Vaccines Announces Presentation at the 2021 Annual Conference
26 Apr 2021 //
PRESS RELEASE
